Back to search results

ADCE-T02 for Advanced Solid Tumors

This study is testing a new investigational drug called ADCE-T02 for people with advanced solid tumors that have continued to grow despite previous treatments. ADCE-T02 is an antibody-drug conjugate (a targeted therapy that delivers a drug directly to cancer cells). The main goals are to find the highest safe dose of ADCE-T02, determine the recommended dose for future studies, and understand any side effects. You may be able to join if you are 18 or older, have an advanced solid tumor that has progressed after at least one treatment, and have a good general health status. The study plans to enroll 210 participants.

Study design
This is a Phase 1 interventional study, meaning all participants will receive ADCE-T02. It aims to enroll 210 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06597721

ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Recruiting
PHASE1Ages 18+InterventionalTreatment
Adcendo ApS
~210 participants
Updated 2026-09-09 on ClinicalTrials.gov
What's tested:ADCE-T02

At a glance

Recruiting sites
14 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Maximum Tolerated Dose (MTD) of ADCE-T02
Measured over Up to 24 months
+2 more outcomes measured

Conditions

Advanced Solid Tumor
PDAC
HNSCC

Explore related trials

Solid Neoplasm

NCT06597721

Where you'd take part

This study runs at 14 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cabrini Hospital

    Malvern, Victoria, Australiano site contact published

    Recruiting

  • Highlands Oncology Group

    Rogers, Arkansasno site contact published

    Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australiano site contact published

    Recruiting

  • Macquarie University Hospital

    Macquarie Park, New South Wales, Australiano site contact published

    Recruiting

  • Massachusetts General Hospital

    Boston, Massachusettsno site contact published

    Recruiting

  • MD Anderson Cancer Center

    Houston, Texasno site contact published

    Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkno site contact published

    Recruiting

  • Peninsula and South Eastern Haematology and Oncology Group (PSEHOG)

    Frankston, Victoria, Australiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Sherri Paxton
[email protected]
1(561) 563-3606
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Well treated basal cell carcinoma or squamous cell carcinoma of the skin.
Low-risk prostate cancer with a Gleason score \< 7 and a PSA level \< 10 ng/mL
Any cancer or in situ cancer the patient has been disease-free for ≥ 2 years.

What this trial measures

  • Maximum Tolerated Dose (MTD) of ADCE-T02Up to 24 months

    The MTD will be determined using DLTs

  • Recommended Expansion Phase Dose (RED) of ADCE-T02Up to 24 months

    The RED will be determined using dose limiting toxicities (DLTs) and all other available study data

  • Type, incidence and severity of Adverse EventsUp to 24 months

    Safety and tolerability profile of ADCE-T02 assessed by the Common Terminology Criteria for Adverse Events v5.0